- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (40)
39 result(s) found for: Medulloblastoma.
Displaying page 1 of 2.
EudraCT Number: 2009-010004-28 | Sponsor Protocol Number: ACNS0331 | Start Date*: 2010-04-14 | ||||||||||||||||
Sponsor Name:COG | ||||||||||||||||||
Full Title: ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblas... | ||||||||||||||||||
Medical condition: Medulloblastoom standard risk | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002560-10 | Sponsor Protocol Number: NOA-07 | Start Date*: 2008-11-04 | |||||||||||
Sponsor Name:Freistaat Bayern, represented by the University of Regensburg | |||||||||||||
Full Title: Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07) | |||||||||||||
Medical condition: Therapy of medulloblastoma of adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004842-14 | Sponsor Protocol Number: CSET2012/1908 | Start Date*: 2013-08-16 | |||||||||||
Sponsor Name:Institut de cancérologie Gustave Roussy | |||||||||||||
Full Title: PHASE I / II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMA | |||||||||||||
Medical condition: High-risk medulloblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000670-22 | Sponsor Protocol Number: 301 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Y-mAbs Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients with Recurrent or Refractory M... | ||||||||||||||||||
Medical condition: Medulloblastoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000801-19 | Sponsor Protocol Number: MBMET_MEYER2017 | Start Date*: 2017-11-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER | |||||||||||||
Full Title: An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medullobla... | |||||||||||||
Medical condition: Metastatic medulloblastoma and other embryonal tumours | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003063-26 | Sponsor Protocol Number: 1634 | Start Date*: 2023-08-10 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I) | |||||||||||||
Medical condition: Newly Diagnosed Medulloblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Temporarily Halted) IT (Ongoing) FR (Prematurely Ended) NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003066-40 | Sponsor Protocol Number: CLDE225C2301 | Start Date*: 2013-02-25 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma | |||||||||||||
Medical condition: Relapsed medulloblastoma characterised by Hedgehog (Hh)-pathway activation | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed) NL (Completed) BE (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004868-30 | Sponsor Protocol Number: PNET5MB | Start Date*: 2013-10-31 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (... | |||||||||||||
Medical condition: Children with medulloblastoma. Medulloblastoma is a highly cellular malignant embryonal neoplasm. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Restarted) BE (Ongoing) IT (Ongoing) FR (Ongoing) FI (Ongoing) SE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) NO (Completed) CZ (Ongoing) NL (Ongoing) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004838-37 | Sponsor Protocol Number: AloCELYVIR | Start Date*: 2021-04-19 | ||||||||||||||||
Sponsor Name:Fundación de Investigación Biomédica Hospital Niño Jesús | ||||||||||||||||||
Full Title: Phase IB clinical trial to assess the safety, tolerability, and preliminary efficacy of AloCELYVIR (Mesenchymal allogenic cells + ICOVIR-5) in children, adolescent and young adults with newly diagn... | ||||||||||||||||||
Medical condition: Newly diagnosed Diffuse Intrinsic Pointine Glioma (DIPG) or Medulloblastoma in relapse/progression in children, adolescents and young adults. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001385-38 | Sponsor Protocol Number: WIN-HYPO2021 | Start Date*: 2021-08-18 | |||||||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||||||||||||
Full Title: RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODG... | |||||||||||||||||||||||
Medical condition: medulloblastoma, Hodgkin and non-Hodgkin lymphomas | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003372-37 | Sponsor Protocol Number: ET11-072 | Start Date*: 2014-06-04 | |||||||||||
Sponsor Name:CENTRE LEON BERARD | |||||||||||||
Full Title: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma pre... | |||||||||||||
Medical condition: Recurrent, progressive or refractory medulloblastoma with activation of the SHH pathway | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004250-17 | Sponsor Protocol Number: RG_18-205,BN3010 | Start Date*: 2019-10-11 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years | |||||||||||||
Medical condition: Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing) DK (Ongoing) IT (Ongoing) NO (Ongoing) NL (Ongoing) BE (Ongoing) SE (Ongoing) CZ (Ongoing) DE (Ongoing) FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003733-38 | Sponsor Protocol Number: ORP-TMZ-I-b | Start Date*: 2021-11-27 | |||||||||||||||||||||||||||||||
Sponsor Name:ORPHELIA Pharma | |||||||||||||||||||||||||||||||||
Full Title: TEMOkids study (ORP-TMZ-I- b): A Population pharmacokinetic, acceptability and safety study for KIMOZO, a paediatric oral suspension of temozolomide | |||||||||||||||||||||||||||||||||
Medical condition: Different pediatric cancers such as malignant glioma and also relapsed or refractory neuroblastoma, rhabdomyosarcoma, medulloblastoma, and Ewing sarcoma, for which treatment with the cytotoxic tem... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023691-33 | Sponsor Protocol Number: MUV-MEMMAT-01 | Start Date*: 2011-05-05 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde | ||
Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma and ATRT | ||
Medical condition: Recurrent/progressive medulloblastoma, ependymoma and ATRT | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) SE (Restarted) CZ (Ongoing) DK (Ongoing) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000095-28 | Sponsor Protocol Number: H3E-MC-JMHW | Start Date*: 2017-03-02 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: A Phase II Study of Pemetrexed in Children with Recurrent Malignancies | ||
Medical condition: Recurrent Malignancies (recurrent solid tumors): Target tumor types were osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma (measurable disease), neuroblastoma (metaiodob... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-000570-78 | Sponsor Protocol Number: 1520 | Start Date*: 2006-07-24 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: PHASE I/II STUDY OF TEMOZOLOMIDE COMBINED WITH ORAL ETOPOSIDE IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA COHORT A , AND MALIGNANT GLIAL TUMOUR C... | |||||||||||||
Medical condition: RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA AND MALIGNANT GLIAL TUMOUR IN CHILDREN AND YOUNG ADULTS | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001512-65 | Sponsor Protocol Number: MEMMATCZ | Start Date*: 2012-06-19 |
Sponsor Name:Masaryk University | ||
Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma | ||
Medical condition: recurrent or progressive medulloblastoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004441-82 | Sponsor Protocol Number: CA209-908 | Start Date*: 2017-06-09 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies | |||||||||||||
Medical condition: Primary central nervous system (CNS) malignancies. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) NO (Completed) NL (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000854-85 | Sponsor Protocol Number: CA045-020 | Start Date*: 2021-04-19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Recurrent or Refractory pediatric cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Completed) IT (Prematurely Ended) Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005476-40 | Sponsor Protocol Number: A5961166 | Start Date*: 2007-02-20 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: PHASE 2 SINGLE-ARM, OPEN LABEL STUDY OF IRINOTECAN IN COMBINATION WITH TEMOZOLOMIDE IN CHILDREN WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA AND IN CHILDREN WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA | |||||||||||||
Medical condition: children with recurrent or refractory medulloblastoma and newly diagnosed high-grade glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) DK (Completed) IT (Prematurely Ended) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.